U toku je je realizacija desetak značajnih kliničkih studija u ovom KBC.
LISTA STUDIJA I NJIHOVI NOSIOCI KAO I KORISNICI REZULTATA:
PUBLIKOVANE KNJIGE U IZDANJU KBC
- UROENTERALNE HIRURŠKE INTERVENCIJE: B. Marković, B.Marković-Ignjatović i D. Ignjatović, 1994 (obim 174 str.)
- TAKTIKA U LEČENJU OBOLJENJA JEDINOG FUNKCIONALNOG BUBREGANJEGOVOG URETERA I MOKRAĆNE BEŠIKE: B.Marković i sar. 1996 (obim 186 str.)
- SINDROMI SA BOLOM U GRUDIMA : S.Stožinić, M.Babić, V.Drecun, I.Lambić , 1997 (obim 216 str.)
- PREVENCIJA MALIGNIH BOLESTI DIGESTIVNIH ORGANA, M.Đorđević, M.Babić,V.Drecun 1997g. (obim 352 str.)
- OSNOVI SAVREMENE ONKOLOGIJE-MODEL PREVENCIJE : M.Đorđević i sar. 2000 (obim 476 str.)
- MEDICINSKI LEKSIKON , M.Babić i sar. 1999 - (obim 1200 str.)
- INTERNA MEDICINA V.Drecun, N.R.Palejev, S.Stožinić i sar. 2000 (obim 388 str.)
- NEW CHALLENGES IN HEALTH CARE: M.Babić, R Zajtchuk i sar.1998 sa Rush Univerzitetom iz Chicaga. (obim 461 str.)
- MODERN HEALTH CARE GLOSSARY: M.Babić,R.Zajtchuk, E.Eckenfels, M.Vučković i sar. 2000 g. sa Rush Univerzitetom iz Chicaga. – (obim 487 str.)
- SKRINING U MEDICINI , M.Babić i sar. 2001 g.- (obim 1000 str.)
- MASKE ANTIFOSFOLIPIDNOG SINDROMA, Lj Stojanović, Beograd, 2001 g.
- AUTOIMUNE BOLESTI, J. Šehfild, Lj. Stojanović, Beograd, 2005
KLINIČKE STUDIJE DIREKTORA KBC VNS dr.sci.med. Vladimira Kovčina
|
CLINICAL TRIAL EXPERIENCE: |
|||||||
therapeutic area
(Alphabetical Order) |
indication |
study phase |
your role in study (e.g. Principal Investigator, study nurse, etc) |
additional study information (Patient
Numbers & Year etc). |
|||
|
|
|
I |
II |
III |
IV |
|
|
|
Adjuvant
trials comparing interferon alpha-2 to gamma to control in malignant melanoma
No. 18871 (EORTC) |
Metastatic
malignant melanoma |
|
|
X |
|
Coinvestigator |
|
|
Cardioprotection
with Cardioxane in patients with breast cancer treated by FAC regimen
(EUROCETUS) |
Breast
Cancer |
|
|
X |
|
Coinvestigator |
|
|
GM-CSF
in treatment of leucopenia induced by aggressive chemotherapy of solid tumors
(SANDOZ) |
Leucopenia
induced by aggressive chemotherapy of solid tumors |
|
X |
|
|
Coinvestigator |
|
|
G-CSF
with the ACVBP regimen for high grade Non-Hodgkin lymphoma (ROCHE) |
High
grade Non-Hodgkin lymphoma |
|
X |
|
|
Coinvestigator |
|
|
Epirubicin-CDDP
vs. VP16-CDDP for small cell lung cancer (CEEOG) |
Small
cell lung cancer |
|
|
X |
|
Coinvestigator |
|
|
CDDP-5FU
regimen for advanced head and neck cancer (Central and East European Oncology
Group - CEEOG) |
Advanced
head and neck cancer |
|
X |
|
|
Coinvestigato |
|
|
UICC
Epidemiology & Prevention Program: Familial Cancer Prevention Project |
Hereditary
cancer of breast, lung and colorectal |
|
|
|
|
Investigator |
1999. |
|
QUASAR1
– UKCCCR study of adjuvant chemotherapy for colorectal cancer |
Adjuvant
chemotherapy for colorectal cancer |
|
|
X |
|
Investigator |
2000. |
|
02-CoFacor
study of first-line chemotherapy for
metastatic colorectal cancer |
Chemotherapy
for metastatic colorectal cancer |
|
|
X |
|
Coinvestigator |
2005. |
|
Phase II
Docetaxel plus Tesmilifene (YMB 1002) in patients with MBC (YM BioSciences) |
First
line chemotherapy for metastatic breast cancer |
|
X |
|
|
Principal investigator |
2006. |
|
Phase III Weekly
Tacosol vs. weekly Paclitaxel in the treatment of MBC (SONUS Pharm) |
Second
line chemotherapy for metastatic breast cancer |
|
|
X |
|
Principal investigator |
2006. |
|
FIND-2 Fentanyl
Inhalation in Neoplastic Disease (LAB Pharma Ltd) |
Breakthrought
pain in maintenance opioid th. |
|
X |
|
|
Principal investigator |
2007. |
|
PBI-1402 and
anemia in cancer patients (ProMetic Bio Sciances) |
Anemia in cancer patients |
Xb |
X |
|
|
Principal investigator |
2007. |
|
MVA-BN HER-2
with 1st or 2nd line treatment for MBC (BN
ImmmunoTherapeutics) |
HER-2 positive metastatic breast cancer |
X |
|
|
|
Principal investigator |
2007. |
|
Phase
III of NOV002-C301in combination with Paclitaxel and Carboplatin (Novelos Therapeutics) |
NSCLC |
|
|
X |
|
Principal investigator |
2007. |
|
A
multyicenter, randomized, duble-blind study of Sunitinib in MCRC receivning
FOLFIRI as first line treatment (Pfizer) |
First
line chemotherapy for metastatic colorectal cancer |
|
|
X |
|
Principal investigator |
2007. |
|
A Phase III, Multicenter, Randomized,
Placebo-Controlled Bevacizumab + Chemotherapy in previously treated MBC (Genetech). |
Second
line MBC |
|
|
X |
|
Principal investigator |
2007. |
|
A
randomized, withdrawal, active and placebo-controlled, duble-blinde oral
CG5503 (Grunenthal GmbH) |
Chronic
tumor related pain |
|
|
X |
|
Principal investigator |
2007. |
|
Randomized,
duble-blinde, biosimilar G-CSF (Filgrastim v.s. Neupogen) in subject
receiving doxorubicin and docetaxel (Mayne Pharma) |
Breast
cancer |
|
|
X |
|
Principal investigator |
2007. |
|
RIBBON2
randomized, placebo-controlled, bevacizumab and chemotherapy in previously
treated MBC (Quintiles) |
Metastatic
breast cancer |
|
|
X |
|
Principal investigator |
2007. |
|
Randomized
Two-Parallel-Arm of E7389 vs Capecitabine in Patients with MBC previously
treated with Antrayclines and Taxanes |
Metastatic
breast cancer |
|
|
X |
|
Principal investigator |
2008. |
|
Registration
Phase III Study of Lucanix in Advanced NSCLC. Randomized, Double-blined,
Placebo controlled. |
NSCLC |
|
|
X |
|
Principal investigator |
2008. |
|
A
Multicenter Phase III Randomized Trial of Adjuvant Therapy For Patient with
HER2-positive BC Comparing Chemoth +
Trastuzumab vs Chth. + Trastuzumab+Bevacizumab |
Breast
Cancer |
|
|
X |
|
Principal investigator |
2009. |
|
Phase
III, Randomised, Placebo-controlled, Double-blind of Once-daily Orally ZD4054 in Non-metastatic Hormone-resistant
Prostate Cancer |
Prostate
Cancer |
|
|
X |
|
Principal investigator |
2009. |
|
QUASAR2
– UKCCCR study of adjuvant chemotherapy for colorectal cancer |
Adjuvant
chemotherapy for colorectal cancer |
|
|
X |
|
Principal investigator |
2009. |
